Paradigm Biocapital Advisors LP Janux Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.62 Billion
- Q4 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 3,515,986 shares of JANX stock, worth $127 Million. This represents 7.18% of its overall portfolio holdings.
Number of Shares
3,515,986
Previous 2,400,574
46.46%
Holding current value
$127 Million
Previous $109 Million
72.61%
% of portfolio
7.18%
Previous 3.93%
Shares
3 transactions
Others Institutions Holding JANX
# of Institutions
228Shares Held
55.1MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$373 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$128 Million0.1% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$110 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$84.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.14MShares$76.9 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.5B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...